http://www.evrs.eu/medias/2010/congress/Branch-Retinal-Vein-Occlusion-Central-Retinal-Vein-Occlusion.flv

Salim Ben Yahia, Riadh Messaoud, Imen Chtioui, Rim Kahloun, Sonia Zaouali, Moncef Khairallah (Monastir, Tunisia)

Advantages:

To manage macular edema secondary to retinal vein occlusion with intravitreal injection of bevacizumab.

Methods:

Thirty eyes of 30 patients with macular edema secondary to retinal vein occlusion (central retinal vein occlusion = 19, branch retinal vein occlusion = 11) were treated with intravitreal injection of 1.25 mg (0.05 mL) of bevacizumab. Outcome measures included changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) measured by optical coherence tomography 6 months after injection.

Effectiveness / Safety:

BCVA improved from 20/160 to 20/80 (P = 0.001) and CMT from 746 µm to 412 µm (P = 0. 001). A repeated injection was necessary in 30% of eyes. No serious adverse events were observed.

Take home message:

Intravitreal bevacizumab is an additional safe and effective treatment for macular edema secondary to retinal vein occlusion, at least in the short term.